Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Key claim: This early-phase trial is determining the maximum tolerated dose and safety of adding venetoclax to FLAMSA plus treosulfan sequential conditioning for allogeneic stem cell transplantation in high-risk MDS, CMML, or secondary AML.
Abstract
This trial aims to find the MTD of Venetoclax when added to Fludarabin, Amsacrine and Ara-C + Treosulfan and to evaluate whether the addition of Venetoclax to sequential conditioning with FLAMSA + Treosulfan is safe for allogeneic blood stem cell transplantation in patients with high-risk MDS, CMML or sAML (FLAMSAClax)
Why this matters
This early-phase trial is determining the maximum tolerated dose and safety of adding venetoclax to FLAMSA plus treosulfan sequential conditioning for allogeneic stem cell transplantation in high-risk MDS, CMML, or secondary AML.